Answers are grounded in this paper and cite their sources.
The composite biomarker, CAPG and GIPC1 in primary breast tumors, predicted disease outcomes and benefit from zoledronate and may facilitate patient selection for adjuvant bisphosphonate treatment.
No takes yet. Share an insight, caveat, or question.
Westbrook et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: